All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

DONATE

Brought to you by

Scientific Education Support logo

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.

SubtypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2024-06-10T09:51:10.000Z

EHA 2024 abstracts: What’s hot in lymphoma and CLL?

By Abhilasha Verma
Jun 10, 2024
Share:

Bookmark this article

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2024 Congress, the Lymphoma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lymphoma and CLL.

Indolent and mantle cell NHL

LB3439

Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: results from the phase 3, double-blind, placebo-controlled ECHO trial

S231

Glofitamab monotherapy in patients with heavily pretreated relapsed or refractory mantle cell lymphoma: updated analysis from a phase I/II study

S232

Primary analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed/refractory follicular lymphoma

S233

Mosunetuzumab demonstrates clinically meaningful outcomes in high-risk patients with heavily pre-treated R/R FL after ≥3 years of follow-up: subgroup analysis of a pivotal phase II study

S234

Epcoritamab induces deep responses in relapsed or refractory (R/R) follicular lymphoma (FL): safety and pooled efficacy data from EPCORE NHL‑1 pivotal and cycle (C) 1 optimization (OPT) FL cohorts

P1138

Preliminary safety and efficacy of BOVEN (zanubrutinib, obinutuzumab, and venetoclax) for frontline therapy for older patients with mantle cell lymphoma

P1146

Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance therapy in FL: novel results from EPCORE NHL‑2 arms 6 and 7


Hodgkin lymphoma

S225

The randomized study GHSG HD21 shows superior tolerability and efficacy of BRECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma

S226

EORTC-1537-COBRA: very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study.

S244

An abbreviated course of A+AVD followed by nivolumab consolidation for frontline therapy in patients with limited stage Hodgkin lymphoma

P1084

Long-term cause-specific mortality in a cohort of 1,435 Hodgkin lymphomas treated at the national adult public cancer program in Chile over a 30-year period

P1093

Brentuximab vedotin - ESHAP significantly increases the metabolic complete remission rate versus ESHAP in relapsed classical Hodgkin lymphoma. Final results of the BRESELIBET prospective trial

P2041

Brentuximab vedotin and bendamustine for relapsed Hodgkin lymphoma: high CMR rate and manageable toxicity


T-cell lymphoma

LB3442

ELA026 targeting of SIRP(+) immune cells results in a high response rate and improved 2-month survival of treatment-naive malignancy-associated hemophagocytic lymphohistiocytosis in a phase 1 study

S245

Outcomes of autologous and allogeneic stem cell transplantation for T-cell lymphoma: an updated analysis of the EBMT lymphoma working party

S247

Valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: efficacy by prior lines of treatment and last treatment outcome from the VALENTINE-PTCL01 study

P2106

Chidamide with azacitidine and CHOP treatment plus auto-ASCT for patients with newly diagnosed peripheral T-cell lymphoma: interim analysis of a prospective, single center, single-arm, phase 2 trial


Aggressive B-NHL

LB3438

Glofitamab plus gemcitabine and oxaliplatin (GLOFIT-GEMOX) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results of a global randomized phase III trial (STARGLO)

S236

Feasibility and clinical efficacy of atezolizumab consolidation in high risk diffuse large B-cell lymphoma: final analysis of the HOVON 151

S237

Englumafusp alfa (CD19/4-1BBL) combined with glofitamab is safe and shows high efficacy in patients with R/R aggressive B-NHL: final results of the dose-escalation part of phase1 trial BP41072

S238

Biomarker-adapted treatment in high-risk large B-cell lymphoma: long-term follow-up of a NORDIC phase II trial

S239

First data from subcutaneous epcoritamab+polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (POLA-R-CHP) for first-line diffuse large B-cell lymphoma (DLBCL): EPCORE NHL-5

S241

TRANSCAR: A real-life outcome study of relapsed/refractory transformed indolent non-Hodgkin lymphoma in the context of CAR T-cells a DESCART analysis

S272

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by ASCT as second-line treatment in patients with R/R large B-cell lymphoma: 3-year follow-up of TRANSFORM

P2086

Efficacy and safety of zanubrutinib combined with R-CHOP regimen in the treatment of newly diagnosed diffuse large b-cell lymphoma with extranodal involvement: a prospective phase II trial in China

P2091

A phase II, single-arm, open-label study to evaluate the safety and efficacy of tafasitamab combined with lenalidomide in patients with relapsed/ refractory diffuse large B-cell lymphoma

P2110

Bruton tyrosine kinase inhibitors and chidamide-combined therapy in relapsed or refractory diffuse large B-cell lymphoma


Chronic lymphocytic leukemia (CLL)

S155

Latest results from an ongoing first-in-human phase 1a/b study of NX-5948, a selective Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory CLL and other B-cell malignancies

S156

Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (SONRO) in combination with zanubrutinib (ZANU) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses

S157

Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study

S158

Characteristics associated with response to lisocabtagene maraleucel (liso‑cel) in patients (pts) with R/R CLL/SLL: exploratory analyses from TRANSCEND CLL 004

S160

Combination of zanubrutinib + venetoclax for treatment-naive (TN) CLL/SLL with del(17P) and/or TP53: preliminary results from SEQUOIA arm D

S161

Minimal residual disease-guided combination of ibrutinib plus venetoclax compared to FCR in untreated patients with CLL of intermediate risk : interim results from the phase II FILO trial.

S162

7-year update on a phase 2 trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL

S163

Single-agent epcoritamab leads to deep responses in patients (pts) with Richter’s transformation (RT): primary results from the EPCORE CLL-1 trial

S164

Combined pirtobrutinib, venetoclax, and obinutuzumab in first-line treatment of patients with chronic lymphocytic leukemia (CLL): a phase 2 trial

P699

6-year time to next treatment (TTNT) extrapolation curve for GLOW study: first-line ibrutinib + venetoclax (I+V) offers long treatment-free period for elderly/unfit CLL patients

P1841

A phase II study of time-limited treatment with acalabrutinib plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia

P1839

Updated results of combination treatment with ibrutinib and venetoclax in patients with chronic lymphocytic leukemia and complex karyotype: 4-year follow-up


EHA 2024 top abstracts

To download this document, click below.

Download here


More about...
EHA 2024

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
70 votes - 16 days left ...

Related articles

Add bookmark

SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL

During the EHA 2024 Hybrid Congress, the Lymphoma Hub spoke to Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked about the latest updates from the SEQUOIA...

Aug 12, 2024
Add bookmark

SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL

During the EHA 2024 Hybrid Congress, the Lymphoma Hub spoke to Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We...

Aug 12, 2024
Add bookmark

EHA2024 congress feed

Stay up to date with the latest developments in lymphoma from the EHA 2024 Congress with our live social media coverage.

Jun 12, 2024
Add bookmark

EHA2024 congress feed

Stay up to date with the latest developments in lymphoma from the EHA 2024 Congress with our live social media coverage.

Jun 12, 2024

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox